Bay Colony Advisory Group, Inc D Biomarin Pharmaceutical Inc Transaction History

Bay Colony Advisory Group, Inc D

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 25, 2019	SELL	$67.4 - $85.11 $451,984 - $570,747	-6,706 Closed	0 $0
Q2 2019 Jul 17, 2019	SELL	$80.35 - $93.9 $15,587 - $18,216	-194 Reduced 2.81%	6,706 $574,000
Q4 2018 Jan 29, 2019	SELL	$80.14 - $106.07 $8,014 - $10,607	-100 Reduced 1.43%	6,900 $588,000
Q3 2018 Nov 05, 2018	SELL	$93.92 - $105.72 $131,488 - $148,008	-1,400 Reduced 16.67%	7,000 $679,000
Q2 2018 Aug 09, 2018	BUY	$76.01 - $99.03 $638,484 - $831,852	8,400 New	8,400 $791,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Bay Colony Advisory Group, Inc D, based on Form 13F filings with the SEC.

Stay updated on Bay Colony Advisory Group, Inc D with notifications on news.